Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study for Children with Acute Lymphoblastic Leukemia Using Study Drug Carfilzomib
Sponsor: Amgen
Enrolling: Male and Female Patients
IRB Number: AAAO2351
U.S. Govt. ID: NCT02303821
Contact: Nobuko Hijiya: 212-305-9770 /
Additional Study Information: The purpose of this study is to learn more about the treatment of children and teenagers whose leukemia has come back (has relapsed) or has not gone away after other treatments (is refractory). Participants will receive the study drug, called carfilzomib in combination with standard chemotherapy, that are dexamethasone, daunorubicin, vincristine and PEG-asparaginase. The study consist of 3 periods: screening, treatment and end of study period. Participants with stable disease or better response at the end of the Induction Cycle will be offered an optional cycle of Consolidation chemotherapy.
This study is closed
Nobuko Hijiya, MD
Do You Qualify?
Does your child have a diagnosis of relapse or refractory acute lymphoblastic leukemia (ALL)? Yes No
Are you between 1 and 21 years of age? Yes No
Have you received prior therapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Nobuko Hijiya